Relationship Between GH Response to Stimuli, Levels of IGF-1, and Final Height

  • R. V. G. García-Mayor
  • L. F. Pérez Mendez
  • C. Páramo
  • R. Luna
  • A. Andrade


Intensive transfusion regimens have significantly improved the prognosis for patients with thalassemia major. However, growth failure and hypogonadism are still major problems. Growth failure is generally accepted as beginning at the age of 10, with a marked decline in the growth rate after the age of 12–14 years [1, 2]. A recent report shows that height impairment occurs before the age of 10 [3]. While it is possible that delayed puberty may be responsible for the failure to grow during the physiological period of puberty, factors determining precocious growth impairment are less clear. Endocrine studies in young children have frequently, but not always, revealed the presence of a normal GH response to provocative stimuli. However, low plasma insulin-like growth factor-1 (IGF-1) activity was found in several studies [4, 5]. The aim of the present study was to investigate the relationship between GH response to pharmacological stimuli, the levels of IgF-1, and final height in thalassemic patients.


Final Height Growth Failure Pubertal Stage Thalassemic Patient Thalassemia Major 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bogna-Pignatti C, De Stefano P, Zonta L, Villo C, De Sanctis V, Melevendi C, Naselle A, Masera G, Terzoli S, Gabitti V, Piga A (1985) Growth and sexual maturation in thalassemia major. J Pediatr 106: 150–155CrossRefGoogle Scholar
  2. 2.
    Kattamis C, Liakopoulus T, Kattamis A (1990) Growth and development in children with thalassemia major. Acta Paediatr Scand [Suppl] 366: 111–117CrossRefGoogle Scholar
  3. 3.
    Cavallo L, De Mattia D, Giobbe T, Liuzzi S, Aquafreda A, Sabato V, Schettini F (1991) Growth in homozigous beta-thalassemic patients. In: Cavallo L, Job J, New MI, (Eds) Serono symposia. Raven New York, pp 47–54Google Scholar
  4. 4.
    Masala A, Meioni T, Gallisani D, Alagna S, Rovassio PP, Rassau S, Milia F (1984) Endocrine functioning in multitransfused prepubertal patients with homozygous beta thalassemia. J Clin Endocrinol Metab 58: 667–670PubMedCrossRefGoogle Scholar
  5. 5.
    Leger J, Girot R, Crosnier H, Postel-Vinay MC, Rappaport R (1989) Normal growth hormone response to growth hormone releasing hormone in children with thalassemia major before puberty: a possible age-related effect. J Clin Endocrinol Metab 69: 453–456PubMedCrossRefGoogle Scholar
  6. 6.
    Herington AC, Werther GA, Mattews RN, Burger HGH (1981) Studies on the possible mechanism for deficiency of nonsuppressible insulin-like activity in thalassemia major. J Clin Endocrinol Metab 52: 393–98PubMedCrossRefGoogle Scholar
  7. 7.
    Caruso-Nicoletti M, Mancuso M, Spadaro G, Lo Presti D, Di Gregorio F, Reitano G (1991) Twelve-hour growth hormone secretion in thalassemic patients. In: Cavallo L, Job J, New MI, (eds) Serono symposia. Raven New York pp 249–252Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • R. V. G. García-Mayor
  • L. F. Pérez Mendez
  • C. Páramo
  • R. Luna
  • A. Andrade

There are no affiliations available

Personalised recommendations